17:56 , May 28, 2019 |  BC Innovations  |  Distillery Therapeutics

Adrenergic receptor inhibitor combo to treat stroke

DISEASE CATEGORY: Neurology INDICATION: Stroke Mouse studies suggest inhibiting ADRA1, ADRA2 and ADRB could help treat acute ischemic stroke. In two mouse models of ischemic stroke, the combination of the ADRA1 antagonist prazosin, the ADRA2...
20:54 , Apr 11, 2019 |  BC Week In Review  |  Company News

Ocugen to go public via Histogenics reverse merger

Ocugen will reverse merge with Histogenics to form a public company focused on discovering, developing and commercializing therapies for rare eye diseases. Ocugen Inc. (Malvern, Pa.) stockholders will own about 90% of the resulting company,...
02:31 , May 18, 2018 |  BC Week In Review  |  Clinical News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
23:41 , May 16, 2018 |  BC Extra  |  Company News

FDA approves US WorldMeds' Lucemyra for opioid withdrawal

FDA approved Lucemyra lofexidine from US WorldMeds LLC (Louisville, Ky.) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. According to the agency, Lucemyra is the first non-opioid drug approved...
17:59 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

Ocugen reports Phase II data for dry eye disease candidate

Ocugen Inc. (Malvern, Pa.) reported data from a Phase II trial showing that dry eye disease candidate OCU310 met the primary endpoint of tolerability over a 12-week period. The company said the trial was not...
17:16 , Mar 30, 2018 |  BC Week In Review  |  Clinical News

FDA panel backs US WorldMeds' opioid withdrawal candidate

US WorldMeds LLC (Louisville, Ky.) said FDA's Psychopharmacologic Drugs Advisory Committee voted 11-1 to recommend approval of an NDA for lofexidine to reduce symptoms associated with opioid withdrawal and facilitation of completion of opioid discontinuation...
18:37 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

FDA panel to review US WorldMeds' opioid withdrawal candidate

FDA said its Psychopharmacologic Drugs Advisory Committee will meet on March 27 to discuss an NDA from US WorldMeds LLC (Lousiville, Ky.) for lofexidine to reduce symptoms associated with opioid withdrawal and facilitation of completion...
19:10 , Mar 7, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Shock / trauma Rat studies suggest the generic ADRA2 agonist/COX inhibitor guanabenz could help treat traumatic brain injury (TBI). In a rat model of TBI, intraperitoneal (i.p.) injection of guanabenz 30 minutes post-injury increased...
21:46 , Dec 1, 2017 |  BC Week In Review  |  Company News

FDA reviewing US WorldMeds’ opioid withdrawal candidate

FDA accepted and granted Priority Review to an NDA for lofexidine from US WorldMeds LLC (Louisville, Ky.) to mitigate symptoms associated with opioid withdrawal. Its PDUFA date is in 2Q18. Lofexidine is an agonist of...
20:37 , Nov 21, 2017 |  BC Extra  |  Company News

FDA reviewing US WorldMeds’ opioid withdrawal candidate

FDA accepted and granted Priority Review to an NDA for lofexidine from US WorldMeds LLC (Louisville, Ky.) to mitigate symptoms associated with opioid withdrawal. Its PDUFA date is in 2Q18. Lofexidine is an agonist of...